On September 7, 2025, IDEAYA Biosciences presented promising Phase 1 data for IDE849 in small cell lung cancer at a major conference, showing a 73.2% overall response rate among 71 evaluable patients. This trial demonstrates significant potential, particularly for those with previously treated cancers, and reports manageable safety profiles.